2024 Review
The Long & Winding Road
The biopharma sector spent much of 2023 wondering whether investor sentiment could get any worse. As new depths were plumbed in October the answer appeared to be yes.
Foreword
M&A Values Continued To Decline During Q4 2024
Modest Final Quarter Completes Shaky Biotech IPO Comeback For 2024
Biopharma VC Fundraising Reached Highest Total Since 2021
Mid-Cap Biopharma’s Biggest Winners And Losers Of 2024
Only Half Of 2024’s Biggest Launches Belong To Big Pharma
How We Help
Contact us for more information